Small cell lung cancer enters the era of precision medicine

Preclinical Pharmacology

Abstract

In this issue of Cancer Cell, Gay et al. describe a molecular classification of small cell lung cancers and extend prior studies that highlight the potential for personalized treatments. Notably, they identify a new “inflamed” subtype that may emerge following acquired chemoresistance but which may become more susceptible to immunotherapy.

Authors

Kathryn Simpson

Kathryn Simpson

Team Lead

Caroline Dive

Caroline Dive

Director